http://orcid.org/0000-0001-8649-1311
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Juan J Fernández-Miranda & Silvia Díaz-Fernández. (2023) Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety. Neuropsychiatric Disease and Treatment 19, pages 2093-2103.
Read now
Read now
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Read now
Heidi C. Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee & Leslie Citrome. (2023) The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of Medical Economics 26:1, pages 316-325.
Read now
Read now
Joel Ketola, Erfan Jahangiri, Helinä Hakko, Pirkko Riipinen & Sami Räsänen. (2022) Assisted living for mentally ill—a systematic literature review and its recommendations. Nordic Journal of Psychiatry 76:6, pages 403-422.
Read now
Read now
Renato de Filippis, Pasquale De Fazio, Raffaele Gaetano, Luca Steardo, Clemente Cedro, Antonio Bruno, Rocco Antonio Zoccali & Maria Rosaria Anna Muscatello. (2021) Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety 20:7, pages 771-790.
Read now
Read now
Articles from other publishers (16)
Samuel R. BuntingKristen ChalmersDaniel YohannaRoyce Lee. (2023) Prescription of Long-Acting Injectable Antipsychotic Medications Among Outpatient Mental Health Care Service Providers. Psychiatric Services 74:11, pages 1146-1153.
Crossref
Crossref
Shaina Schwartz, Sun Lee, Erin Baily Coble, Colton Troxler, Samantha Toscano & Archana Kumar. (2023) Time‐to‐therapy discontinuation in patients newly diagnosed with schizophrenia initiated on long‐acting injectable versus oral dopamine receptor blocking agents. Early Intervention in Psychiatry 17:9, pages 921-928.
Crossref
Crossref
John M. Kane, Anna Chen, Sangtaeck Lim, Marko A. Mychaskiw, Marc Tian, Yitong Wang, Mark Suett & Jose M. Rubio. (2023) Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. International Clinical Psychopharmacology 38:4, pages 240-248.
Crossref
Crossref
Christoph U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Hélène Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre & Panagiotis Mavros. (2023) Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia 9:1.
Crossref
Crossref
Nagesh Pai, Andrew B McGeachie, Andrea Puig, Tom H-W Huang & Prachi Brahmbhatt. (2022) Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia: A comparative study in the Australian context. Australasian Psychiatry 31:1, pages 76-81.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2022) The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up. Biomedicines 11:1, pages 42.
Crossref
Crossref
Alex Z. Fu, Jacqueline A. Pesa, Susan Lakey & Carmela Benson. (2022) Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry 22:1.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2022) Effectiveness of More Personalized, Case-Managed, and Multicomponent Treatment for Patients with Severe Schizophrenia Compared to the Standard Treatment: A Ten-Year Follow-Up. Journal of Personalized Medicine 12:7, pages 1101.
Crossref
Crossref
Betül UYAR, Abdullah ATLI & Derya GÜL BİLEN. (2022) Clinical use of long-acting antipsychotics for the treatment of bipolar disorder type I patientsBipolar bozukluk tip I hastalarının tedavisinde uzun etkili antipsikotiklerin klinik kullanımı. Cukurova Medical Journal 47:2, pages 844-851.
Crossref
Crossref
Roger W. Sommi, Bhaskar Rege, Angela Wehr, Sejal Faldu, Yangchun Du & Peter J. Weiden. (2020) Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. CNS Spectrums 27:3, pages 262-267.
Crossref
Crossref
Péter Takács, Péter Kunovszki, Valeria Timtschenko, László Fehér, Tamás Balázs, Ramóna Hegyi, Pál Czobor & István Bitter. (2022) Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update. Schizophrenia Bulletin Open 3:1.
Crossref
Crossref
Silvia Díaz-Fernández, Francisco López-Muñoz & Juan J. Fernández-Miranda. (2021) Psychosocial and Pharmacological Approaches for Improving Treatment Adherence and Outcomes in People With Severe Schizophrenia: A 10-Year Follow-up. Journal of Psychiatric Practice 27:6, pages 417-426.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2021) Adherence, Tolerability and Effective Doses of Aripiprazole Once-monthly in the Long-term Treatment of Patients with Severe Schizophrenia. Current Pharmaceutical Design 27:39, pages 4078-4085.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández & Francisco López-Muñoz. (2021) Oral Versus Long-Acting Injectable Antipsychotic Treatment for People With Severe Schizophrenia. Journal of Nervous & Mental Disease 209:5, pages 330-335.
Crossref
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study. Clinical Drug Investigation 40:4, pages 355-375.
Crossref
Crossref
Etem Erdal Erşan. (2019) Hospitalization and Some Sociodemographic Characteristics of Patients Registered with a Community Mental Health Center. Community Mental Health Journal 56:3, pages 498-505.
Crossref
Crossref